Clinical Trial Update: Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma [Phase 3]

View source ↗

Summary

This clinical trial update notes a Phase 3 study evaluating inhaled Dornase alfa to reduce respiratory failure after severe trauma, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Trauma
• Respiratory Distress Syndrome

Drugs mentioned

• Pulmozyme (dornase alfa)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Multiple Trauma, Respiratory Distress Syndrome, Adult | Phase 3 | Status: RECRUITING